CN110691599B - 使用脂多糖的脑功能改善剂、食品和药品 - Google Patents

使用脂多糖的脑功能改善剂、食品和药品 Download PDF

Info

Publication number
CN110691599B
CN110691599B CN201780091325.7A CN201780091325A CN110691599B CN 110691599 B CN110691599 B CN 110691599B CN 201780091325 A CN201780091325 A CN 201780091325A CN 110691599 B CN110691599 B CN 110691599B
Authority
CN
China
Prior art keywords
brain
lipopolysaccharide
group
pantoea
food
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780091325.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN110691599A (zh
Inventor
杣源一郎
稻川裕之
河内千惠
小林优多郎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Combination Of Natural Immune Control Technology
Biomedical Research Group Inc
Kagawa University
Original Assignee
Research Combination Of Natural Immune Control Technology
Biomedical Research Group Inc
Kagawa University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Combination Of Natural Immune Control Technology, Biomedical Research Group Inc, Kagawa University filed Critical Research Combination Of Natural Immune Control Technology
Publication of CN110691599A publication Critical patent/CN110691599A/zh
Application granted granted Critical
Publication of CN110691599B publication Critical patent/CN110691599B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
CN201780091325.7A 2017-05-28 2017-12-04 使用脂多糖的脑功能改善剂、食品和药品 Active CN110691599B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017105133A JP6998133B2 (ja) 2017-05-28 2017-05-28 リポ多糖を用いた脳機能改善剤、食品及び医薬品
JP2017-105133 2017-05-28
PCT/JP2017/043429 WO2018220886A1 (ja) 2017-05-28 2017-12-04 リポ多糖を用いた脳機能改善剤、食品及び医薬品

Publications (2)

Publication Number Publication Date
CN110691599A CN110691599A (zh) 2020-01-14
CN110691599B true CN110691599B (zh) 2023-05-02

Family

ID=64455394

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780091325.7A Active CN110691599B (zh) 2017-05-28 2017-12-04 使用脂多糖的脑功能改善剂、食品和药品

Country Status (8)

Country Link
US (1) US11278564B2 (enExample)
EP (1) EP3643314B1 (enExample)
JP (2) JP6998133B2 (enExample)
KR (2) KR20200011490A (enExample)
CN (1) CN110691599B (enExample)
BR (1) BR112019024953A2 (enExample)
IL (1) IL270936B2 (enExample)
WO (1) WO2018220886A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6998133B2 (ja) * 2017-05-28 2022-01-18 自然免疫制御技術研究組合 リポ多糖を用いた脳機能改善剤、食品及び医薬品
WO2022104088A2 (en) * 2020-11-13 2022-05-19 National Health Research Institutes Method for treating amyloidogenic disease
JP7679216B2 (ja) * 2021-04-07 2025-05-19 有限会社バイオメディカルリサーチグループ リポ多糖製造方法、リポ多糖、及びその配合物
KR20250025712A (ko) 2022-06-22 2025-02-24 겐이치로 소마 당뇨병성 인지증에 대한 예방약 및 치료약
KR102555274B1 (ko) 2022-12-03 2023-07-13 김환배 분리형 측면 미세먼지 집진휀스로 세척이 용이한 고기구이기
US20260102478A1 (en) * 2024-10-14 2026-04-16 Longhorn Vaccines And Diagnostics, Llc Vaccines and Antibodies for the Treatment and Prevention of Neurodegenerative Disorders and Inflammation Related Health Conditions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106714827A (zh) * 2014-10-02 2017-05-24 日东电工株式会社 经皮给药用疫苗药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030938A1 (ja) 2003-09-26 2005-04-07 Biomedical Research Group Inc. 発酵及び培養方法、植物発酵エキス、植物発酵エキス末並びに該植物発酵エキス配合物
JP2016193865A (ja) 2015-03-31 2016-11-17 キリン株式会社 ミクログリア貪食活性亢進のための組成物及びミクログリア貪食活性亢進作用の予測方法
JP6780240B2 (ja) 2015-12-11 2020-11-04 株式会社リコー 制御装置、液体を吐出する装置、印刷物の生産方法及びプログラム
JP6998133B2 (ja) 2017-05-28 2022-01-18 自然免疫制御技術研究組合 リポ多糖を用いた脳機能改善剤、食品及び医薬品

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106714827A (zh) * 2014-10-02 2017-05-24 日东电工株式会社 经皮给药用疫苗药物组合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A Lipopolysaccharide from Pantoea Agglomerans Is a Promising Adjuvant for Sublingual Vaccines to Induce Systemic and Mucosal Immune Responses in Mice via TLR4 Pathway;Masahiro Fukasaka等;《pone》;20150515;全文 *
A mixture of Salacia oblonga extract and IP-PA1 reduces fasting plasma glucose (FPG) and low-density lipoprotein (LDL) cholesterol levels;Kazue Nakata等;《Nutrition Research and Practice》;20111231;全文 *
Effect of Lipopolysaccharide Derived from Pantoea agglomerans on the Phagocytic Activity of Amyloid β by Primary Murine Microglial Cells;YUTARO KOBAYASHI等;《ANTICANCER RESEARCH》;20161231;第3693-3698页 *
Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer’s disease-related pathology;Jean-Philippe Michaud等;《PNAS》;20130129;全文 *

Also Published As

Publication number Publication date
KR20220025912A (ko) 2022-03-03
CN110691599A (zh) 2020-01-14
IL270936B1 (en) 2023-06-01
JP2018199643A (ja) 2018-12-20
JP2021169506A (ja) 2021-10-28
WO2018220886A1 (ja) 2018-12-06
BR112019024953A2 (pt) 2020-06-23
US11278564B2 (en) 2022-03-22
EP3643314C0 (en) 2023-08-30
IL270936A (en) 2020-01-30
KR20200011490A (ko) 2020-02-03
JP6998133B2 (ja) 2022-01-18
EP3643314A1 (en) 2020-04-29
IL270936B2 (en) 2023-10-01
EP3643314A4 (en) 2021-04-07
US20200179436A1 (en) 2020-06-11
JP7809461B2 (ja) 2026-02-02
EP3643314B1 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
JP7809461B2 (ja) リポ多糖を用いた脳機能改善剤、食品及び医薬品
JP7153950B2 (ja) 神経発達障害療法
JP7503179B2 (ja) インスリン抵抗性改善用組成物
CN103402524A (zh) 用于改善认知功能的组合剂
ES2208330T3 (es) Composiciones para modular la respuesta nmune y para el tratamiento de la enfermedad inflamatoria.
WO2024106716A1 (ko) 2'-푸코실락토오스를 포함하는 치매 개선 또는 치료용 조성물
JP5769912B2 (ja) 認知障害を伴う疾患又は状態の予防又は治療用の組成物
US20240115530A1 (en) Administration of baiba to increase benefit of losing weight of intermittent fasting
ES2973249T3 (es) Composición que comprende cepa de Agathobaculum sp. como ingrediente efectivo para la prevención, alivio o tratamiento del trastorno del espectro autista
JP7144052B2 (ja) 掻痒性皮膚疾患の予防又は治療薬
AU2019241803A1 (en) Compositions for preventing or treating cognitive impairment-related disease comprising mumefural
HK40015331B (en) Brain function-improving agent, food, and medicine using lipopolysaccharide
HK40015331A (en) Brain function-improving agent, food, and medicine using lipopolysaccharide
CN105497021A (zh) 胺类化合物治疗焦虑障碍的医药用途
EP4039329A1 (en) Composition for suppression of decrease in muscle mass, prevention of decrease therein, maintenance thereof, recovery thereof or increase therein
JP7181695B2 (ja) 抗認知症剤及び短期記憶障害改善／抑制剤
CN108159032A (zh) 二甲双胍在制备预防和/或治疗阿片类毒品成瘾药物中的应用和药物及制备方法
US20220096415A1 (en) Composition for Improving Cognitive Function
Nakayama Appetite Enhancement and Digestive Enzyme Secretion Promoting Effects of Carnitine
TWI646965B (zh) Use of Pleurotus eryngii for the treatment or prevention of dementia and its symptoms
Dhanalakshmi et al. Protective effect of Picrorrhiza kurroa on ochratoxin A induced oxidative stress in chickens
JP2012006877A (ja) 認知症治療薬
JP2011213700A (ja) 認知症改善用組成物
WO2019146652A1 (ja) 抗ｉ型アレルギー剤、及び肥満細胞又は好塩基球の脱顆粒抑制剤、並びに抗認知症剤、及び短期記憶障害改善／抑制剤
JP2018008895A (ja) 認知機能低下抑制又は予防剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40015331

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant